News Center

Home page

Peak Report

News reports

I'm predestined with spikes

Release time:

2020-08-14

I have a predestined relationship with Peak

■ Jinxi Pharmaceutical Factory Yang Ming

This year is the 60th anniversary of Peak's start-up and the 20th year that I joined the big family of Peak. Inadvertently looking back, many things seem like yesterday, feeling a lot. If you can sum it up in one sentence, it is-I am really predestined with spikes.

My fate with Peak has to start from 1998 5 . At that time, I worked in the biochemical pharmaceutical factory under the Jinhua Meat Union Factory. In order to diversify, Jianfeng Group carried out an acquisition merger of the biochemical pharmaceutical factory this year. At that time, the company organized a strong working group to enter the meat joint factory and conducted a series of negotiations. In late 5 , Du Zihong, then chairman of the group company, made an enthusiastic speech at the kick-off meeting of all employees of the biochemical pharmaceutical factory. In addition to introducing the overall situation of Jianfeng Group, he also said to us earnestly: "If you join Jianfeng Group, it is like a daughter getting married. The palms and backs of hands are all meat." This speech undoubtedly gave us a reassurance, not only gave us a preliminary understanding of the spike, but also eliminated everyone's worries. We feel very warm.

Merger is a big deal. As the financial director of biochemical pharmaceutical factory, my first task is to actively cooperate with the enterprises of both sides to carry out the work, do a good job in the factory's assets and capital verification, and clean up the creditor's rights and debts. These complicated and trivial preparations laid the foundation for the smooth handover of the biochemical plant.

1998 9 September , Biochemical Factory "transformed" into Jiangbei Pharmaceutical Factory under Jianfeng. I also officially became a member of Jianfeng Group. The company attaches great importance to our employees, and arranges corresponding positions according to the nature, characteristics and skills of each person's original work, so as to make the best use of their talents. I first served as the financial supervisor in Jiangbei Factory, and then transferred to Jiangnan Pharmaceutical Factory as the financial supervisor at the end of 1999 , 1 according to the needs of my work. 2003 3# In September, I was transferred to the office manager of Jiangnan Factory, in charge of factory discipline inspection, labor discipline assessment and the formulation of training plans for the whole factory. In addition, I also served as a member of the party branch organization of Jiangnan Factory, responsible for the daily work of party affairs and trade unions for eleven years.

2014 4 , the construction of Jinxi Pharmaceutical Factory was completed, and the "moving" of Jiangnan Factory was another big project. Due to the consideration of production convergence, each workshop was relocated step by step, and the workshops and personnel at the back of the queue were temporarily transferred to Qiubin Pharmaceutical Factory. I was also one of the "left-behind" personnel and continued to be responsible for the follow-up management of the office. In the following year, on the day of 7 and 1 , the original land of Jiangnan pharmaceutical factory was handed over. I also went to work in the general office of Jinxi pharmaceutical factory, which was regarded as a formal "return.

Now, I am mainly responsible for the attendance management, inspection and assessment of the whole factory's personnel, cleaning personnel and guard management, and also serve as the guidance of the correspondent of the factory's "Peak News". In the past two years, with the increasingly smooth management and production work of Jinxi Factory, the quantity and quality of communication reports have also been continuously improved, ranking first among the subordinate enterprises of the group.

Compared with my colleagues who came from the era of cement's single main business, I am a "new" peak person. However, compared with younger colleagues, I am an "old" peak person who has worked in peak for 20 years. Over the years, I deeply feel the development and changes of Jianfeng Group, especially the continuous progress of Jianfeng Pharmaceutical. I feel honored and proud of the brilliant achievements of the peak, and also feel honored and happy for my "relationship" with the peak and for being able to work in the peak. In another two and a half years, I will retire. I will continue to stand on my post, do my job well, and contribute to the development of Jianfeng Pharmaceutical. I also firmly believe that Jianfeng Group can create another brilliant, "one hundred years of peak" dream will be able to achieve!

More information

Monitoring Report of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project

2020

07-30

Monitoring Report of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project

2020

07-31

Monitoring Report of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project

2020

07-31

Daye Jianfeng Cement Co., Ltd. Kiln End Flue Gas Desulfurization Project Completion Environmental Protection Acceptance Publicity

Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution

2020

07-31

Spike New Drug Approved for Registration

On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)

2020

07-31

Spike New Drug Approved for Registration

2020

07-31

< 1...30 31 32...61 > 跳转到页